8-K: GoodRx CFO Karsten Voermann Secures New Employment Agreement and Special Bonus

GoodRx Holdings, Inc. has entered into a new employment agreement with Chief Financial Officer Karsten Voermann, including a special bonus and equity awards.

Summary

• GoodRx Holdings, Inc. has formalized a new employment agreement with its Chief Financial Officer, Karsten Voermann, effective March 4, 2024.
• The agreement replaces a previous offer letter from February 12, 2020, and continues Mr. Voermann's at-will employment.
• Mr. Voermann's annual base salary remains at $450,000, with potential adjustments by the Board of Directors.
• He is eligible for an annual cash incentive bonus targeted at 100% of his base salary, contingent on performance goals set by the Board.
• In March 2024, Mr. Voermann will receive equity awards valued at $5,000,000, split equally between stock options and restricted stock units.
• These equity awards will vest over time, with 25% vesting on January 8, 2025, and the remainder vesting quarterly thereafter.
• The agreement includes severance benefits if Mr. Voermann is terminated without cause or resigns for good reason, including 12 months of base salary, a pro-rated bonus, and COBRA coverage.
• A special one-time bonus of $162,792 was approved for Mr. Voermann in recognition of his contributions during the 2023 fiscal year.
• This bonus is separate from his annual performance-based bonus.

Sentiment

Score: 8

Explanation: The document reflects a positive and stable situation with the company securing its CFO with a new agreement and a bonus for past performance. The terms are standard and expected for this type of role.

Positives

• The new employment agreement provides clarity and stability for the company's CFO position.
• The equity awards and bonus structure are designed to incentivize performance and retention.
• The severance package provides a safety net for Mr. Voermann in case of involuntary termination.
• The special bonus recognizes Mr. Voermann's significant contributions to the company.

Risks

• The agreement includes a 'best pay' provision related to Section 280G of the Internal Revenue Code, which could result in higher costs for the company if certain conditions are met.
• The vesting schedule for the equity awards could create a risk of Mr. Voermann leaving the company after a portion of the awards have vested.

Future Outlook

The agreement ensures the continued employment of the CFO and provides incentives for performance and retention. The vesting schedule for equity awards is designed to align the CFO's interests with the long-term success of the company.

Management Comments

• The Board approved a one-time discretionary bonus in the amount of $162,792 to Mr. Voermann in recognition of his individual contributions to the Company during the Company's fiscal year 2023.

Industry Context

This type of executive employment agreement is standard practice for publicly traded companies to secure and incentivize key personnel. The inclusion of equity awards and performance-based bonuses is common in the tech and healthcare industries to align executive interests with shareholder value.

Comparison to Industry Standards

• The base salary of $450,000 for a CFO at a company of GoodRx's size is within the typical range for the industry.
• The 100% target bonus is also a common incentive structure for executive roles.
• The equity award of $5,000,000 is a significant incentive, but not unusual for a CFO at a publicly traded company, especially one with a growth focus.
• The vesting schedule of 25% on the first anniversary and then quarterly is a standard approach to ensure long-term commitment.
• The severance package is also typical, providing a safety net for the executive while protecting the company's interests.

Stakeholder Impact

• Shareholders may view the new agreement positively as it ensures the continued leadership of the CFO.
• Employees may see the agreement as a sign of stability and commitment to the executive team.
• The agreement does not directly impact customers or suppliers.

Next Steps

• The equity awards will be granted to Mr. Voermann in March 2024.
• The Board will review Mr. Voermann's base salary annually.
• Mr. Voermann will continue to perform his duties as CFO under the terms of the new agreement.

Key Dates

Keywords

employment agreement, CFO, Karsten Voermann, executive compensation, stock options, restricted stock units, bonus, severance, GoodRx, incentive bonus